• 1
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 2347.
  • 2
    Scher HJ, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in prostate cancer. J Clin Oncol. 1993; 11: 15661572.
  • 3
    Dawson N, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose of megestrol acetate for patients with advanced prostate carcinoma: Cancer and Leukemia Group B study 9181. Cancer. 2000; 88: 825834.
  • 4
    Tannock I, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996; 14: 17561764.
  • 5
    Kantoff P, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: the results of CALGB 9182. J Clin Oncol. 1999; 17: 25062513.
  • 6
    Kelly WK, Scher HI, Mazumdar M, Vlamis V, Scwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993; 11: 607615.
  • 7
    Small EJ, McMillan A, Meyer M, et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol. 2001; 19: 13041311.
  • 8
    Scher HI, Kelly WK, Zhang ZF, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 1999; 91: 244251.
  • 9
    Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol. 1995; 13: 29442953.
  • 10
    Bauer KS, Figg WD, Hamilton JM, et al. A pharmacokinetically guided phase II study of carboxyamido-triazole (CAI) in androgen independent prostate cancer. Clin Cancer Res. 1999; 5: 23242329.
  • 11
    Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997; 15: 31563163.
  • 12
    Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol. 1999; 17: 16641671.
  • 13
    Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol. 2001; 19: 25092516.
  • 14
    Petrylak DP, Shelton GB, England-Owen C, et al. Response and preliminary survival results of a phase II study of docetaxel and estramustine in patients with androgen-independent prostate cancer. Proc Am Soc Clin Oncol. 2000; 19: 334a.
  • 15
    Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Eisenberger MA. A phase II study evaluating docetaxel and one day estramustine phosphate in patients with hormone refractory prostate cancer: updated preliminary analysis. Proc Am Soc Clin Oncol. 2000; 19: 346a.
  • 16
    Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 1994; 12: 20052012.
  • 17
    Seidman AD, Scher HL, Petrylak DP, Dershaw DD, Curley T. Estramustine and vinblastine: use of prostatic specific antigen as a clinical trial endpoint in hormone refractory prostate cancer. J Urol. 1992; 147: 931934.
  • 18
    Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001; 19: 4453.
  • 19
    Ellerhorst JA, Tu SM, Amato RJ, et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 1997; 3: 23712376.
  • 20
    Petrylak DP, Macarthur R, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999; 17: 958967.
  • 21
    Raghavan D, Cox K, Pearson BS, et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol. 1993; 72: 625628.
  • 22
    Saxman S, Ansari R, Drasga R, et al. Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study. Cancer. 1992; 70: 24882492.
  • 23
    Stephens RL, Vaughn C, Lane M, et al. Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study. Cancer. 1984; 53: 406410.
  • 24
    Bracarda S, Tonato M, Rosi P, et al. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Cancer. 2000; 88: 14381444.
  • 25
    Maulard-Durdux C, Dufour B, Hennequin C, Chretien Y, Delanian S, Housset M. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer. 1996; 77: 11441148.
  • 26
    Schmidt JD, Scott WW, Gibbons R, et al. Chemotherapy programs of National Prostatic Program (NPCP). Cancer. 1980; 45: 19371946.
  • 27
    Soloway MS, deKernion JB, Gibbons RP, et al. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J Urol. 1981; 125: 664667.
  • 28
    Saika T, Kusaka N, Tsushima T, et al. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Inter J Urol. 2001; 8: 290294.
  • 29
    Nishimura K, Nonomura N, Yasunaga Y, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 2000; 89: 25702576.
  • 30
    Bubley G, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA working group. J Clin Oncol. 1999; 17: 34613467.
  • 31
    Picus J, Schultz M. Docetaxel as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol. 1999; 26 (Suppl): 1418.
  • 32
    Ghosh BK. A comparison of some approximate confidence intervals for the binomial parameter. J Am Stat Assoc 1979; 74: 894900.
  • 33
    Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 34
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep. 1966; 60: 163170.
  • 35
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc, B. 1972; 4: 187220.
  • 36
    Therneau TM, Grambsch PM. Modeling survival data. New York: Springer, 2000.
  • 37
    Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81: 515526.
  • 38
    Venables WN, Ripley BD. Modern applied statistics with Splus, 3rd ed. New York: Springer, 1999.